SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Meta Expands AI Training With Employee Activity Tracking Tools 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
ALISO VIEJO, Calif., March 09, 2017 -- NVISION Eye Centers – a national leader in ophthalmic treatments and services, is pleased to announce the introduction of Avedro Photrexa® Viscous, Photrexa® and the KXL System used in corneal collagen cross-linking for the treatment of keratoconus. The procedure has the ability to both stabilize and strengthen the cornea, halting or slowing the progression of keratoconus in the early phases of the condition. It can also improve vision in some patients with a more progressed stage of the condition.
“Keratoconus is a progressive thinning and distortion of the cornea that can result in significant visual loss and may lead to the need for a corneal transplant.” states Dr. Tom Tooma, founder of NVISION Eye Centers. “NVISION surgeons are treating patients who are suffering from progressive keratoconus. We are excited to offer a long term solution to our patients with this condition.”
The announcement follows the recent approval that Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received from the U.S. Food and Drug Administration (FDA).
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is one of the largest providers of LASIK and cataract surgery in the U.S., with 26 centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.
